智通财经APP讯，奥星生命科技(06118)发布截至2024年12月31日止年度年度业绩，持续经营业务收入15亿元(人民币，下同)，同比减少14.93%;股东应占溢利1607.9万元，上年同期股东应占亏损1.13亿元，同比扭亏为盈;每股基本盈利0.03元。
公告称，收益减少主要由于集团在2023年全年的订单量大幅下降约32.7%，导致期初未完工合同减少。然而，与2023年取得的亏损相比，2024年的税后净利润显示已转亏为盈， 2024年的订单承接量与2023年同期相比增加12.1%。该项转亏为盈乃由于管理层坚毅不屈的努力，能够应对中国市场激烈竞争的挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.